Ecnoglutide
Sources
registry, as of 2025-04-30Stale
https://clinicaltrials.gov/study/NCT05813795
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 664. Conditions Weight Management. The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
ClinicalTrials.gov NCT05813795 protocol and results modules
registry, as of 2026-08-31Stale
https://clinicaltrials.gov/study/NCT07734311
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA). Overall status RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 360. Conditions Knee Osteoarthritis; Obesity. The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.
ClinicalTrials.gov NCT07734311 protocol and results modules
registry, as of 2026-09-23Stale
https://clinicaltrials.gov/study/NCT07836270
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 192. Conditions Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities. The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
ClinicalTrials.gov NCT07836270 protocol and results modules
registry, as of 2026-09-16Stale
https://clinicaltrials.gov/study/NCT07243171
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 126. Conditions Overweight and/or Obesity; Weight Management. The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
ClinicalTrials.gov NCT07243171 protocol and results modules
registry, as of 2025-09-10Stale
https://clinicaltrials.gov/study/NCT05184322
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults. Overall status COMPLETED. Phases PHASE1. Lead sponsor Sciwind Biosciences APAC CO Pty. Ltd.. Enrollment 87. Conditions Obesity; Type 2 Diabetes Mellitus. XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
ClinicalTrials.gov NCT05184322 protocol and results modules
publication, as of 2026-08-07Stale
https://pubmed.ncbi.nlm.nih.gov/42310888/
Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Evaluate ecnoglutide (XW003) effects on rosuvastatin and digoxin pharmacokinetics (PKs) in healthy adu
PMID 42310888